Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…Abstract Number: 744 • 2016 ACR/ARHP Annual Meeting
Factors Related to Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus
Background/Purpose: To identify factors associated with blood concentrations of hydroxychloroquine (HCQ) and its major metabolite, N-desethylhydroxychloroquine (DHCQ), in patients with systemic lupus erythematosus (SLE) receiving…Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…Abstract Number: 747 • 2016 ACR/ARHP Annual Meeting
The Long-Term Outcomes on Leflunomide Treatment in Patients with Lupus Nephritis: A Twelve-Year Follow-up Study
Background/Purpose: Leflunomide(LEF) is an effective immunosuppressant. In China, one phase III study has reported that compared with cyclophosphamide, LEF in combination with prednisone was effective in the induction…Abstract Number: 748 • 2016 ACR/ARHP Annual Meeting
A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus
Background/Purpose: Intravenous (IV) belimumab 10 mg/kg is approved in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) as add-on to standard SLE therapy (SoC). This…Abstract Number: 749 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Background/Purpose: The addition of an anti-TWEAK monoclonal antibody to SOC LN therapy did not improve 52-week RR rates in proliferative LN despite observed pharmacodynamic effects.…Abstract Number: 750 • 2016 ACR/ARHP Annual Meeting
Predictors of Corticosteroid Use in the Systemic Lupus International Collaborating Clinics Inception Cohort – a Multivariate Analysis
Factors Associated With Oral Glucocorticoid Use in Systemic Lupus Erythematosus : Results From a Large International Inception Cohort. Jayne Little1, Mark Lunt1, Ben Parker1, Ian…Abstract Number: 751 • 2016 ACR/ARHP Annual Meeting
Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Background/Purpose: We evaluated the relationships between disease activity measures and C4d split products on erythrocytes (EC4d) in SLE subjects from a subset of the Hopkins…Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…Abstract Number: 753 • 2016 ACR/ARHP Annual Meeting
Vitamin D Improves Systolic Blood Pressure in SLE
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Both a cohort study and a randomized clinical trial have proven that Vitamin D supplementation improves SLE…Abstract Number: 754 • 2016 ACR/ARHP Annual Meeting
The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus
Background/Purpose: Anti-malarial agents (AM) prevent damage in patients with systemic lupus erythematosus (SLE). We aimed to examine whether the duration of AM therapy early in…Abstract Number: 755 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort
Background/Purpose: Hydroxychloroquine (HCQ) is recommended for all patients with SLE. While patient reported adherence rates are between 51-64%, blood HCQ level testing may be a…Abstract Number: 756 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…Abstract Number: 757 • 2016 ACR/ARHP Annual Meeting
Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)
Background/Purpose: Multiple outcome measures have been utilized in SLE clinical trials. Consistency of response assessed by different instruments enhances confidence in the efficacy of pharmacologic…
ACR Meeting Abstracts